Literature DB >> 18824293

Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma.

Ka Ho Tam1, Zhen Fan Yang, Chi Keung Lau, Chi Tat Lam, Roberta W C Pang, Ronnie T P Poon.   

Abstract

The present study investigated the effect of mammalian target of rapamycin (mTOR) inhibition on HCC cells in vitro and in vivo, either alone or in combination with cytotoxic agents. In vitro, HCC cell lines were exposed to RAD001, an mTOR inhibitor, either alone or in combination with cisplatin. Alone, RAD001 suppressed cell proliferation in all cell lines tested, but did not induce apoptosis. RAD001 in combination with cisplatin induced a significant increase in the number of apoptotic cells, downregulated the expression of pro-survival molecules, Bcl-2, survivin and cyclinD1, and increased the cleavage of PARP, compared to RAD001 or cisplatin alone. Transfection of p53 into the Hep3B cell line increased the sensitivity of tumor cells to cisplatin. The suppression of HCC tumor growth in vivo was enhanced by RAD001 combined with cisplatin, accompanied by a significant increase in the number of apoptotic cells in tumor tissues. This study demonstrates that inhibition of mTOR suppresses tumor growth and sensitizes tumor cells to chemocytotoxic agents.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18824293     DOI: 10.1016/j.canlet.2008.08.018

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Ariel Km Chow; Thomas Cc Yau; Lui Ng; Andrew Cy Chu; Wai-Lun Law; Ronnie Tp Poon; Roberta Wc Pang
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

2.  Effect of APE1 and XRCC1 gene polymorphism on susceptibility to hepatocellular carcinoma and sensitivity to cisplatin.

Authors:  Zhihong Yang; Juan Zhao
Journal:  Int J Clin Exp Med       Date:  2015-06-15

3.  Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients.

Authors:  Doaa Ali Abdelmonsif; Ahmed S Sultan; Wessam F El-Hadidy; Dina Mohamed Abdallah
Journal:  Mol Diagn Ther       Date:  2018-02       Impact factor: 4.074

4.  Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.

Authors:  Bryan Wei Chen; Wei Chen; Hui Liang; Hao Liu; Chao Liang; Xiao Zhi; Li-Qiang Hu; Xia-Zhen Yu; Tao Wei; Tao Ma; Fei Xue; Lei Zheng; Bin Zhao; Xin-Hua Feng; Xue-Li Bai; Ting-Bo Liang
Journal:  Mol Cancer Ther       Date:  2015-05-29       Impact factor: 6.261

5.  Ribosomal RACK1 promotes chemoresistance and growth in human hepatocellular carcinoma.

Authors:  Yuanyuan Ruan; Linlin Sun; Yuqing Hao; Lijing Wang; Jiejie Xu; Wen Zhang; Jianhui Xie; Liang Guo; Lei Zhou; Xiaojing Yun; Hongguang Zhu; Aiguo Shen; Jianxin Gu
Journal:  J Clin Invest       Date:  2012-06-01       Impact factor: 14.808

6.  Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma.

Authors:  Min Li; Huawen Sun; Lujun Song; Xiaodong Gao; Wenju Chang; Xinyu Qin
Journal:  Oncol Lett       Date:  2012-09-21       Impact factor: 2.967

7.  Cardamonin enhances the anti-proliferative effect of cisplatin on ovarian cancer.

Authors:  Peiguang Niu; Daohua Shi; Shusheng Zhang; Yanting Zhu; Jintuo Zhou
Journal:  Oncol Lett       Date:  2018-01-08       Impact factor: 2.967

Review 8.  Glyceraldehyde-3-phosphate dehydrogenase: a promising target for molecular therapy in hepatocellular carcinoma.

Authors:  Shanmugasundaram Ganapathy-Kanniappan; Rani Kunjithapatham; Jean-Francois Geschwind
Journal:  Oncotarget       Date:  2012-09

9.  microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin.

Authors:  Zhongxian Wang; Zhou Ting; Ya Li; Gang Chen; Yunping Lu; Xing Hao
Journal:  Oncol Lett       Date:  2013-07-08       Impact factor: 2.967

10.  Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.

Authors:  N Charette; C De Saeger; Y Horsmans; I Leclercq; P Stärkel
Journal:  Cell Death Dis       Date:  2013-01-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.